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Abstract
BACKGROUND—Few epidemiological studies have explored the relationship between orofacial 
clefts and bronchodilators. We assessed whether mothers who used bronchodilators during early 
pregnancy were at an increased risk of delivering infants with orofacial clefts.
METHODS—We used National Birth Defects Prevention Study case–control data from mothers 
of 2711 infants with orofacial clefts and 6482 mothers of live born infants without birth defects, 
delivered during 1997 through 2005. Information on medication use from 3 months before 
pregnancy through delivery was collected using a standardized interview . Logistic regression was 
used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for maternal 
bronchodilator use during the periconceptional period (1 month before pregnancy through the third 
month of pregnancy) while controlling for other covariates.
RESULTS—We observed an association between maternal bronchodilator use during the 
periconceptional period and cleft lip only (CLO) (aOR = 1.77, 95% CI: 1.08–2.88). The risk of 
cleft palate only (CPO) (aOR = 1.53, 95% CI: 0.99–2.37) was elevated but was not statistically 
significant. No association was observed for maternal bronchodilator use and the risk of cleft lip 
with cleft palate (aOR = 0.78, 95% CI: 0.46–1.31). The most commonly used bronchodilator was 
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albuterol (88.7%). Maternal albuterol use was associated with CLO (aOR = 1.79, 95% CI: 1.07–
2.99) and CPO (aOR = 1.65, 95% CI: 1.06–2.58).
CONCLUSIONS—We observed a statistically significant association between maternal 
bronchodilator use during the periconceptional period and the risk of CLO after controlling for 
other risk factors. It is unclear whether the increased odds ratios observed in this study are due to 
the bronchodilators, the severity of asthma, or both, or to chance alone. Further studies to 
disentangle the role of asthma or asthma medications would help clarify these findings.
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Introduction
Asthma is one of the most common chronic conditions that can complicate pregnancy. In 
recent national surveys (2000–2004) in the USA, ~8.4–8.8% of pregnant women reported 
asthma and 4.1% reported an asthma attack in the previous year (Kwon et al., 2006). From 
the same national surveys, pregnant women who were younger, unmarried, of lower income, 
Puerto Rican or who lived in the northeast USA experienced more asthma attacks or asthma-
related emergency visits during the previous year (Kwon et al., 2006). The National Asthma 
Education and Prevention Program recommends the continued use of appropriate asthma 
medications during pregnancy (NAEEP, 2005). Studies have suggested that well-controlled 
asthma is less likely to result in adverse reproductive outcomes than poorly controlled 
asthma (Murphy et al., 2005). Several epidemiologic studies have reported increased risks of 
adverse pregnancy outcomes among women with asthma, including pre-eclampsia, 
intrauterine growth restriction, preterm birth, perinatal death and congenital malformations 
(Demissie et al., 1998; Kallén et al., 2000, 2007; Tamasi et al., 2006).
Nevertheless, 39% of women with asthma reported discontinuing their asthma medication, 
reducing medication dosage or both during pregnancy in a survey of 501 asthmatic women 
of child-bearing age (Chambers, 2003).
Asthma is treated with anti-inflammatory agents to prevent acute exacerbations and with 
bronchodilators to control symptoms (NAEEP, 2005). Anti-inflammatory agents include 
inhaled and oral corticosteroids, mast cell stabilizers and leukotrine modifiers. 
Bronchodilators improve ventilation to the lungs by relaxing contractions of the smooth 
muscle of the bronchioles. Bronchodilators include β2-adrenegic agonists (beta-agonists), 
anticholinergic agents and theophylline; of these, beta-agonists are most commonly used to 
treat asthma. Bronchodilators are categorized as either quick-relief or rescue medications 
(short-acting beta-agonists and anticholinergics) or long-term control medications (long-
acting beta-agonists and theophylline). Teratogenic effects, including cleft palate, were 
found when bronchodilators (albuterol, theophylline) were administered to pregnant mice or 
rabbits (Szabo et al., 1975; Shibata et al., 2000). In epidemiological studies, the use of 
maternal oral corticosteroids (anti-inflammatory medications) during early pregnancy has 
been found to be associated with an increased risk of cleft lip, cleft palate or both 
(Rodriguez-Panilla and Martinez-Frias, 1998; Park-Willie et al., 2000; Carmichael et al., 
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2007); however, no known studies have evaluated associations between bronchodilators and 
specific birth defects.
Orofacial clefts are birth defects in which the tissues of the palate and/or lip fail to fuse 
properly during fetal development. In this study, we divided orofacial clefts into three 
groups: cleft lip with cleft palate (CLP), cleft lip only (CLO) and cleft palate only (CPO). As 
most studies do not separate CLP from CLO, it is unclear to what extent the epidemiologic 
features and origin of these defects differ. A recent study (Harville et al., 2007) suggests that 
epidemiologic assessments of orofacial clefts should, when possible, include separate 
analyses of CLP and CLO. In the USA, prevalence estimates of cleft lip with or without cleft 
palate (CL/P) and CPO are 10.48 and 6.39 per 10 000 live births, respectively (CDC, 2006). 
The etiology of these birth defects is not well understood; however, many studies suggest 
that both genetic and environmental factors are involved. A specific gene, interferon 
regulatory factor 6, was identified in 2004 (Zucchero et al., 2004), and polymorphisms in 
this gene result in a 3-fold increased risk of these defects. Several studies involving the 
exploration and analysis of candidate genes such as TK32B, EVC, PTCH1, SUMO1, TGFA 
and TNS1 have provided further evidence of their role in the causation of non-syndromic 
orofacial clefts (Beaty et al., 2009; Carter et al., 2009; Sull et al., 2010). In previous studies, 
orofacial clefts have been associated with older maternal and/or paternal age (Honein et al., 
2007; Green et al., 2010), exposure to organic solvents (Gordon and Shy, 1981; Chevrier et 
al., 2006), oral corticosteroid use (Carmichael et al., 2007), alcohol consumption (Romitti et 
al., 2007), cigarette smoking (Bille et al., 2007; Honein et al., 2007; Shi et al., 2007), less 
use of multivitamins (Itikala et al., 2001), race/ethnicity (Khoury et al., 1983; Croen et al., 
1998; Forrester and Merz, 2004), epilepsy and antiepileptic drugs (Dravet et al., 1992; 
Abrishamchian et al., 1994), and family history of orofacial clefts (Leite and Koifman, 
2009).
We are not aware of previous studies that explore the link between maternal bronchodilator 
use and orofacial clefts. The objective of the study is to assess whether mothers who used 
bronchodilators during early pregnancy were at an increased risk of delivering infants with 
orofacial clefts.
Materials and Methods
Design and study population
This analysis used data from the ongoing National Birth Defects Prevention Study 
(NBDPS), a multi-site, population-based, case–control study designed to evaluate the 
genetic and environmental risk factors associated with more than 30 categories of birth 
defects in the USA. Detailed methodology used in the NBDPS is described elsewhere (Yoon 
et al., 2001). Infants with single-gene disorders or chromosome abnormalities are excluded 
from the study. Adopted children, those in foster care, or those whose mothers did not speak 
English or Spanish are also excluded from the study. Clinical information abstracted from 
medical records was reviewed by clinical geneticists at each center, and strict criteria were 
used to determine case eligibility. In addition, a single clinical geneticist (S.A.R.) classified 
infants with orofacial clefts as isolated (an orofacial cleft, but no other major birth defects) 
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or as having multiple defects (one or more major, unrelated birth defects in addition to 
orofacial cleft) (Rasmussen et al., 2003).
The study population in this analysis included infants with orofacial clefts identified from 
birth defects surveillance systems in 10 states [Arkansas, California, Georgia (Centers for 
Disease Control and Prevention), Iowa, Massachusetts, New Jersey, New York, North 
Carolina, Texas and Utah]. Case infants included live births, fetal deaths of 20 or more 
weeks of gestation or greater than 550 g (nine sites), and elective terminations (eight sites). 
Control infants were live born infants without birth defects randomly selected from birth 
certificates or birth hospital records in the same geographic areas as the case infants. A total 
of 2773 case infants and 6652 control infants had estimated dates of delivery (EDD) from 1 
October 1997 through 31 December 2005. Infants (n = 6) whose mothers used the beta-
agonist terbutaline (which is used also to prevent preterm labor) and infants (n = 73) whose 
mothers did not complete the medications questions were excluded from the analysis. Also 
excluded were infants (n = 153) whose mothers used an anti-inflammatory medication 
commonly used to treat asthma but did not report use of a bronchodilator. All activities 
involved in this study were approved by the institutional review boards of each of the 
participating study centers and the Centers for Disease Control and Prevention.
Exposure assessment
Asthma medications are generally classified as bronchodilator or anti-inflammatory. The 
Boston University Slone Epidemiology Center Drug Dictionary, a computerized database of 
prescription and non-prescription drugs that links drug products to their respective active 
ingredients, was used to classify asthma medications.
In this study, we defined ‘exposed’ as any mother who reported use of a bronchodilator at 
least once during the period 1 month before conception through the third month of her 
pregnancy. This four-month period was designated as the periconceptional period in the 
analysis. It includes the time of lip and palate formation. Included as bronchodilators were 
all beta-agonists, anticholinergics and methyxanthines (theophylline) commonly used to 
treat asthma. In addition, we looked at the effect of using both bronchodilator and anti-
inflammatory asthma medication during the periconceptional period, which may be an 
indicator of asthma severity. Anti-inflammatory medications included were those commonly 
used to treat asthma. Anti-inflammatory asthma medications reported by study mothers 
included fluticasone, prednisone, beclomethasone, triamcinolone, cromolyn sodium, 
budesonide, montelukast, zafirlukast, methylprednisolone, flunisolide and prednisolone.
Mothers who reported using bronchodilators ‘as needed’ rather than reporting the timing of 
exposure were subjected to close examination to minimize misclassification. Those who 
used bronchodilators ‘as needed’, but the period of use could not be determined were 
removed from the main analysis. We attempted to determine the route of administration of 
the bronchodilator (oral or inhaled) based on the mother’s report or known formulation of 
the medication. However, because the route of administration was not available for many 
participants, the variable was not considered in the final analysis. In addition, we compared 
odds ratios for maternal bronchodilator use during the periconceptional period to those for 
use only after the third month of pregnancy (4th–9th months of pregnancy).
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Statistical analysis and potential confounders
We examined the crude association between orofacial clefts and maternal and infant 
characteristics, which included maternal age at delivery, BMI, parity, race/ethnicity, 
education, alcohol consumption, smoking habits, folic acid-containing vitamin use, cocaine/
crack use, marijuana use, fever during the first trimester, as well as infant sex. Associations 
between orofacial clefts and the use of vasoactive medicines, which included aspirin, 
ibuprofen, acetaminophen, pseudoephedrine, phenylpropanolamine and 
methylenedioxymethamphetamine, were also examined. In addition, we looked at 
associations between maternal and infant characteristics and bronchodilator use.
Bronchodilator use only and the combined use of bronchodilators and anti-inflammatory 
medications (fluticasone, prednisone, beclomethasone, triamcinolone, cromolyn sodium, 
budesonide, montelukast, zafirlukast, methylprednisolone, flunisolide and prednisolone) 
were evaluated in separate models for each type of orofacial cleft, including both isolated 
and multiple defects, as well as for isolated defects only. Exposure to albuterol use was 
examined separately for each type of orofacial cleft. Mothers who used anti-inflammatory 
medications were excluded from the analysis of bronchodilator use and orofacial clefts. The 
adjusted odd ratios (aOR) and 95% confidence intervals (CIs) were estimated using 
unconditional logistic regression. The following covariates were included in all models 
because of evidence in the literature that they may be associated with orofacial clefts or use 
of bronchodilators: maternal age at delivery, race/ethnicity, level of education, alcohol 
consumption, smoking habits, marijuana use, folic acid-containing vitamin use, vasoactive 
medication use and infant sex.
Results
A total of 2711 case infants, which includes 397 with multiple defects, were identified after 
excluding 2 case infants whose mothers used terbutaline (which is used also to prevent 
preterm labor), 14 case infants whose mothers did not complete the medication questions 
and 46 case infants whose mothers reported an anti-inflammatory medication commonly 
used to treat asthma but did not report use of a bronchodilator. Of the case infants included 
in the analysis, 614 had CLO, 938 had CPO and 1159 had CLP. A total of 6482 control 
infants were included in the final analysis after excluding 59 whose mothers did not 
complete the medication questions and 4 whose mothers used terbutaline and 107 infants 
whose mothers reported an anti-inflammatory medication commonly used to treat asthma 
but did not report use of a bronchodilator. Participation rates for the study were 74% among 
mothers of infants with orofacial clefts and 67% among control mothers. The median time 
between EDD and interview was 9 months for case mothers and 7 months for control 
mothers.
Table I shows the use of different bronchodilators among case and control mothers. Of the 
mothers who used bronchodilators (n = 247), 81 case and 138 control mothers used albuterol 
during the periconceptional period. Salmeterol was the second most frequently used asthma 
medication among case (n = 6) and control (n = 21) mothers.
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The associations between maternal and infant characteristics and orofacial clefts are shown 
in Table II. Compared with controls, crude analysis revealed that younger maternal age (≤29 
years old), low maternal BMI (< 18.5), low level of maternal education (≤12 years), 
maternal Hispanic race/ethnicity, male infant sex, maternal smoking and a family history 
were significantly associated with CLP; maternal use of folic acid-containing vitamins 
showed a protective effect with CLP, and maternal Hispanic race/ethnicity showed a 
protective effect with CLO and CPO. There was a protective effect between non-Hispanic 
black race/ethnicity and CLO, CPO and CLP. Maternal BMI, smoking, vasoactive 
medication use, male infant sex and a family history were associated with CLO. Finally, 
maternal smoking, female infant sex and a family history were associated with CPO. There 
was no significant difference between mothers of case infants with CLO, CPO and CLP, and 
mothers of control infants with regard to, parity, use of cocaine/crack, use of marijuana, 
consumption of alcohol during the periconceptional period or maternal fever in the first 
trimester of pregnancy.
The aORs of the associations between each type of orofacial cleft and bronchodilator use 
during the periconceptional period are presented in Table III. The results suggest an 
association between maternal bronchodilator use only and CLO (aOR = 1.77, 95% CI: 1.08–
2.88). The association was slightly higher when only isolated case infants were examined 
(aOR = 1.88, 95% CI: 1.15–3.07). The risk of CPO (aOR = 1.53, 95% CI: 0.99–2.37) was 
elevated but was not statistically significant. No significant association was found between 
maternal bronchodilator use and CLP (aOR = 0.78, 95% CI: 0.46–1.31) nor when we 
grouped CLO and CLP (aOR = 1.11, 95% CI: 0.76–1.62; data not shown) after controlling 
for maternal age at delivery, race/ethnicity, level of education, alcohol consumption, 
smoking habits, marijuana use, folic acid-containing vitamin use, maternal use of any 
vasoactive medication as well as infant sex. Additionally, no significant associations were 
found between maternal use of both bronchodilators and anti-inflammatory medications 
during the periconceptional period and CLO (aOR = 1.06, 95% CI: 0.38–3.01), CPO (aOR = 
0.85, 95% CI: 0.33–2.18) or CLP (aOR = 1.26, 95% CI: 0.60–2.65). Table III also shows the 
risks associated with maternal albuterol use. A statistically significant association was found 
between maternal albuterol use and both CLO (aOR = 1.79, 95% CI: 1.07–2.99) and CPO 
(aOR = 1.65, 95% CI: 1.06–2.58). For isolated cases only, the odds ratio for maternal 
albuterol use and CLO was slightly higher (aOR = 1.90, 95% CI: 1.14–3.18) but for CPO the 
odds ratio was lower and not significant (aOR = 1.48, 95% CI: 0.89–2.47). The odds ratios 
among mothers who used bronchodilators during the 4th–9th months of pregnancy only 
were not significant. When mothers with family history of orofacial clefts (n = 19) were 
removed from the analysis, the odds ratios were unchanged.
Discussion
Mothers of infants with CLO were statistically significantly more likely to use 
bronchodilators during the periconceptional period than mothers of control infants. In 
addition, a statistically significant association was observed between maternal albuterol use 
and both CLO and CPO. While the risk of CPO for infants whose mothers used any 
bronchodilators was elevated but not statistically significant, the risk of CPO was 
statistically significant for infants whose mothers used albuterol only. No statistical 
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association was found with maternal bronchodilator use when we grouped CLO and CLP. 
Among mothers who reported bronchodilator use, most reported using albuterol. The odds 
ratios were slightly higher when we examined infants classified as having isolated CLO. No 
associations were observed between the use of both bronchodilators and anti-inflammatory 
medications during the periconceptional period and the any type of orofacial cleft.
Previous studies that assessed the teratogenic effects of medication on orofacial clefts have 
focused on the use of corticosteroids (oral, inhaled and topical) and have produced mixed 
results. Carmichael et al. (2007) examined corticosteroid use in the NBDPS and found a 
moderately increased risk of CL/P (aOR = 1.7, 95% CI: 1.1–2.6) and no association for CPO 
(aOR = 0.5, 95% CI: 0.2–1.3). In contrast, in a population-based, case–control study 
conducted by Czeizel et al. (1997), no statistically significant associations were observed 
between corticosteroid treatment during the second and third months of pregnancy and a 
number of different congenital anomalies, including CL/P. We are not aware of other 
epidemiological studies that investigate the teratogenic effects of bronchodilators as a group 
or albuterol individually on orofacial clefts.
Human placental transfer of albuterol and other bronchodilators has been demonstrated in 
vitro (Nandakumaran et al., 1981; Sodha and Schneider, 1983; Omarini et al., 1993). The US 
Food and Drug Administration has classified albuterol and salmeterol as pregnancy category 
C mediations (Product information, 2000). Pregnancy category C is given to medications for 
which animal studies have shown harm or no animal studies are available and no adequate 
and well-controlled studies in humans are available. The second bronchodilator most 
commonly reported by pregnant women is salmeterol (10.9%), a long-acting, inhaled beta-
agonist widely recommended during pregnancy. Among mothers of infants with CLO, none 
reported using salmeterol during the periconceptional period. Based on a study by Wilton et 
al. (1998), among 47 infants whose mothers used salmeterol during the first trimester of 
pregnancy, the only birth defect found was one case of Aarskog syndrome, a single-gene 
condition unlikely to be associated with salmeterol exposure.
The present analysis has several strengths. The study is population-based and has a large 
sample size, allowing us to look at individual types of bronchodilators. In addition, the 
NBDPS benefits from a systematic case review by clinical geneticists at each center to 
ensure case eligibility and use of a detailed interview instrument to collect data on many 
potentially confounding variables. Finally, studies have shown that CLO, CPO and CLP may 
not be associated with the same risk factors at the same level or share the same etiology 
(Carmichael et al., 2007; Harville et al., 2007; Romitti et al., 2007). Our in-depth case 
classification allowed us to analyze these defects separately and to also examine isolated 
orofacial clefts.
This study has certain limitations worth noting. Medication use was ascertained only by 
maternal self-report, and no information is available on the dosage. Recall bias cannot be 
ruled out since mothers of affected children may attempt to find a causal explanation such as 
medication use during pregnancy, compared with mothers of infants without birth defects 
(Werler et al., 1989; Rockenbauer et al., 2001). To minimize this potential bias, the interview 
included questions about specific types of medicines, as well as the timing of these 
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exposures by using a pregnancy calendar. Although this analysis has controlled for some 
confounders, the results may be influenced by factors not accounted for. Asthma status/
severity, for which data were not available in this study, may have also played a role. Recent 
studies have suggested that maternal asthma (Blais et al., 2010) or the combination of both 
asthma (controlled versus uncontrolled and severe versus mild) and asthma medication use, 
particularly bronchodilators (Lin et al., 2009), may play a role in the risk of specific 
congenital malformations.
In conclusion, our results reveal a statistically significant association between maternal 
bronchodilator use during the periconceptional period and the risk of CLO after controlling 
for other risk factors. However, it is unclear whether the association observed in this study is 
due to the bronchodilators, the severity of asthma or both or to chance alone. There was no 
association between the use of both bronchodilators and anti-inflammatory medications and 
orofacial clefts. The use of both types of asthma medication may indicate more severe 
asthma; however, it may also indicate better therapeutic control of asthma, which in turn 
might explain the lack of association observed in our study. Further studies to disentangle 
the role of asthma or asthma medications or both are needed to help clarify these findings.
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Table I
Maternal bronchodilator use during the periconceptional period among infants with orofacial clefts and non-
malformed control infants, NBDPS 1997–2005.
Bronchodilator use (n = 247)a n %b Cases, n = 89 (%) Controls, n = 158 (%)
Albuterol 219 88.7 81 (3.05)c 138 (2.17)
Salmeterol 27 10.9 6 (0.23) 21 (0.34)
Pirbuterol 6 2.4 3 (0.12) 3 (0.05)
Ipratropium bromide 5 2.0 1 (0.04) 4 (0.06)
Theophylline 5 2.0 2 (0.08) 3 (0.05)
Epinephrine (Primatene) 2 0.8 1 (0.04) 1 (0.02)
Metaproterenol 1 0.4 0 (0.00) 1 (0.02)
Levalbuterol 0 0 0 0
a
n includes bronchodilator users regardless of use of an anti-inflammatory.
b
Percentage who used a specific bronchodilator out of all bronchodilator users.
Total is not equal to 100% due to multiple medication use.
c
P < 0.05 in χ2 test between cases and controls.
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Table II
Maternal and infant characteristics among infants with orofacial clefts and non-malformed control infants, 
NBDPS Study, 1997–2005.
Controls (n = 6482) n 
(%)
Cleft lip only Cases (n 
= 614) n (%)
Cleft palate only Cases 
(n = 938) n (%)
Cleft lip with cleft 
palate Cases (n = 1159) 
n (%)
Maternal age at delivery
 ≤24 years old 2188 (33.8) 215 (35.0) 295 (31.5) 470 (40.6)a
 25–29 years old 1697 (26.2) 167 (27.2) 252 (26.9) 307 (26.5)a
 > 29 years old (Ref) 2597 (40.1) 232 (37.8) 391 (41.7) 382 (33.0)
Maternal BMI
 < 18.5 kg/m2 350 (5.6) 47 (8.0)a 54 (6.0) 83 (7.5)a
 ≥18.5 kg/m2 5868 (94.4) 540 (92.0) 853 (94.1) 1020 (92.5)
Parity
 0 births 2608 (40.3) 259 (42.2) 370 (39.5) 471 (40.7)
 ≥1 birth 3868 (59.7) 355 (57.8) 566 (60.5) 686 (59.3)
Maternal race/ethnicity
 White non-Hispanic (Ref) 3809 (59.0) 411 (67.1) 607 (64.9) 667 (57.8)
 Black non-Hispanic 756 (11.7) 37 (6.0)a 69 (7.4)a 70 (6.1)a
 Hispanic 1472 (22.8) 125 (20.4)a 188 (20.1)a 341 (29.5)a
 Others 417 (6.5) 40 (6.5) 71 (7.6) 77 (6.7)
Maternal level of education
 ≤12 years 2722 (42.3) 255 (41.6) 415 (44.6) 621 (53.9)a
 > 12 years 3714 (57.7) 358 (58.4) 515 (55.4) 532 (46.1)
Maternal alcohol consumptionb
 Yes 2399 (37.3) 251 (41.0) 372 (40.1) 421 (36.6)
 No 4026 (62.7) 362 (59.1) 556 (59.9) 729 (63.4)
Infant sex
 Male 3276 (50.6) 397 (64.8)a 424 (45.3)a 770 (66.7)a
 Female 3201 (49.4) 216 (35.2) 513 (54.8) 385 (33.3)
Maternal smokingb
 Yes 1246 (19.3) 150 (24.4)a 219 (23.5)a 298 (25.8)a
 No 5204 (80.7) 464 (75.6) 712 (76.5) 856 (74.2)
Folic acid containing vitamins
 Yes 3257 (50.3) 309 (50.3) 467 (49.8) 515 (44.4)a
 No 3225 (49.8) 305 (49.7) 471 (50.2) 644 (55.6)
Cocaine or crack useb
 Yes 46 (0.7) 6 (1.0) 10 (1.1) 7 (0.6)
 No 6404 (99.3) 608 (99.0) 921 (98.9) 1146 (99.4)
Any vasoactive medicationsb,c













Munsie et al. Page 13
Controls (n = 6482) n 
(%)
Cleft lip only Cases (n 
= 614) n (%)
Cleft palate only Cases 
(n = 938) n (%)
Cleft lip with cleft 
palate Cases (n = 1159) 
n (%)
 Yes 1619 (25.0) 186 (30.3)a 262 (27.9) 291(25.1)
 No 4863 (75.0) 428 (69.7) 676 (72.1) 868 (74.9)
Marijuana useb
 Yes 312 (4.8) 40 (6.5) 50 (5.4) 64 (5.6)
 No 6137 (95.2) 574 (93.5) 882 (94.6) 1089 (94.5)
Fever in first trimester
 Yes 690 (10.6) 79 (12.9) 114 (12.2) 129 (11.1)
 No 5792 (89.4) 535 (87.1) 824 (87.9) 1030 (88.9)
Family history of orofacial cleft
 Yes 1 (0.0) 2 (0.3)a 5 (0.5)a 11 (1.0)a
 No 6481 (100.0) 612 (99.7) 933 (99.5) 1148 (99.1)
a
P < 0.05 in χ2 test.
b
During the periconceptional period.
c
Use of any of the following vasoactive medications: aspirin, ibuprofen, acetaminophen, pseudoephedrine, phenylpropanolamine and 
methylenedioxymethamphetamine.
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